The durability of sitagliptin in elderly patients with type 2 diabetes
Ching-Jung Hsieh, Feng-Chih Shen Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan Aim: To evaluate the durability of sitagli...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ac817c4695f84725b3ff6c9f1349316b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ac817c4695f84725b3ff6c9f1349316b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ac817c4695f84725b3ff6c9f1349316b2021-12-02T06:36:18ZThe durability of sitagliptin in elderly patients with type 2 diabetes1178-1998https://doaj.org/article/ac817c4695f84725b3ff6c9f1349316b2014-11-01T00:00:00Zhttps://www.dovepress.com/the-durability-of-sitagliptin-in-elderly-patients-withnbsptype-2-diabe-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Ching-Jung Hsieh, Feng-Chih Shen Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan Aim: To evaluate the durability of sitagliptin and to assess changes in clinical chronic complications following sitagliptin monotherapy for 48 months in elderly patients with type 2 diabetes mellitus (T2DM).Subjects and methods: We enrolled 76 drug-naïve patients (40 women and 36 men; mean age: 71.3±11.7 years) with T2DM who received 25–100 mg of sitagliptin therapy from an outpatient clinic. The observational period for each patient was >48 months, beginning at the time sitagliptin therapy was initiated. The following were measured or performed at the beginning of each year: body mass index; serum total cholesterol, low-density lipoprotein, high-density lipoprotein; triglyceride levels; creatinine (Cr) levels; urine albumin and urine Cr; nonmydriatic fundusgraphy; and semiquantified neuropathy. The fasting plasma glucose and glycated hemoglobin (HbA1c) was measured every 3–6 months.Results: The change in HbA1c was significantly reduced after 6 months of therapy (7.1%±0.8% to 6.3%±0.2%). No changes in fasting plasma glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, body mass index, and microvascular complications were apparent. Using repeated measures to test the sequential changes in HbA1c from month 6 to month 48, the test of within-subjects effect was not significant (P=0.34).Conclusion: Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients. This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM. Keywords: type 2 diabetes mellitus, sitagliptin, oral antidiabetic drugs, dipeptidyl peptidase IV inhibitorHsieh CJShen FCDove Medical PressarticleType 2 diabetesSitagliptinOral anti-diabetic drugsDipeptidyl peptidase IV inhibitorGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 1905-1911 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Type 2 diabetes Sitagliptin Oral anti-diabetic drugs Dipeptidyl peptidase IV inhibitor Geriatrics RC952-954.6 |
| spellingShingle |
Type 2 diabetes Sitagliptin Oral anti-diabetic drugs Dipeptidyl peptidase IV inhibitor Geriatrics RC952-954.6 Hsieh CJ Shen FC The durability of sitagliptin in elderly patients with type 2 diabetes |
| description |
Ching-Jung Hsieh, Feng-Chih Shen Division of Endocrinology and Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan Aim: To evaluate the durability of sitagliptin and to assess changes in clinical chronic complications following sitagliptin monotherapy for 48 months in elderly patients with type 2 diabetes mellitus (T2DM).Subjects and methods: We enrolled 76 drug-naïve patients (40 women and 36 men; mean age: 71.3±11.7 years) with T2DM who received 25–100 mg of sitagliptin therapy from an outpatient clinic. The observational period for each patient was >48 months, beginning at the time sitagliptin therapy was initiated. The following were measured or performed at the beginning of each year: body mass index; serum total cholesterol, low-density lipoprotein, high-density lipoprotein; triglyceride levels; creatinine (Cr) levels; urine albumin and urine Cr; nonmydriatic fundusgraphy; and semiquantified neuropathy. The fasting plasma glucose and glycated hemoglobin (HbA1c) was measured every 3–6 months.Results: The change in HbA1c was significantly reduced after 6 months of therapy (7.1%±0.8% to 6.3%±0.2%). No changes in fasting plasma glucose, Cr, serum total cholesterol, triglyceride, low-density lipoprotein, high-density lipoprotein, body mass index, and microvascular complications were apparent. Using repeated measures to test the sequential changes in HbA1c from month 6 to month 48, the test of within-subjects effect was not significant (P=0.34).Conclusion: Sitagliptin has a durable effect and stabilizes microvascular complication progression in elderly patients. This study can provide useful data for clinicians and health care professionals using sitagliptin monotherapy in the treatment of elderly patients with T2DM. Keywords: type 2 diabetes mellitus, sitagliptin, oral antidiabetic drugs, dipeptidyl peptidase IV inhibitor |
| format |
article |
| author |
Hsieh CJ Shen FC |
| author_facet |
Hsieh CJ Shen FC |
| author_sort |
Hsieh CJ |
| title |
The durability of sitagliptin in elderly patients with type 2 diabetes |
| title_short |
The durability of sitagliptin in elderly patients with type 2 diabetes |
| title_full |
The durability of sitagliptin in elderly patients with type 2 diabetes |
| title_fullStr |
The durability of sitagliptin in elderly patients with type 2 diabetes |
| title_full_unstemmed |
The durability of sitagliptin in elderly patients with type 2 diabetes |
| title_sort |
durability of sitagliptin in elderly patients with type 2 diabetes |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://doaj.org/article/ac817c4695f84725b3ff6c9f1349316b |
| work_keys_str_mv |
AT hsiehcj thedurabilityofsitagliptininelderlypatientswithnbsptype2diabetes AT shenfc thedurabilityofsitagliptininelderlypatientswithnbsptype2diabetes AT hsiehcj durabilityofsitagliptininelderlypatientswithnbsptype2diabetes AT shenfc durabilityofsitagliptininelderlypatientswithnbsptype2diabetes |
| _version_ |
1718399833220317184 |